Evidence map›Paper›PMID 42573030›Full record

SynthesisThe Cochrane database of systematic reviews2026

Glucagon-like peptide-1 receptor agonist-based regimens compared with metformin-based regimens for preventing cardiovascular disease in adults with type 2 diabetes mellitus.

Sana Ahmed, Sandra P McCollin, Arturo Martí-Carvajal, Monica Akus, David W Baron, Sara Abdul Razzaq, Paige Scudder, Elizabeth J Honigsberg, Saifuddin Nasir, Kangning Peng and 1 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sana AhmedDepartment of Food and Nutrition, University of Delhi, New Delhi, India.ORCID https://orcid.org/0000-0002-1658-6574
Sandra P McCollinPharmacy Enterprise, Cambridge Health Alliance, Cambridge, Massachusetts, USA.
Arturo Martí-CarvajalCátedra Rectoral de Medicina Basada en la Evidencia, Universidad de Carabobo, Valencia, Venezuela.ORCID https://orcid.org/0000-0001-8677-3351
Monica AkusPharmacy Enterprise, Cambridge Health Alliance, Cambridge, Massachusetts, USA.
David W BaronDepartment of Internal Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, Massachusetts, USA.
Sara Abdul RazzaqDepartment of Thoracic Surgery, Tufts Medical Center, Boston, Massachusetts, USA.
Paige ScudderHirsh Health Sciences Library, Tufts University, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-0513-3315
Elizabeth J HonigsbergDepartment of Medicine, Dartmouth Health, Lebanon, New Hampshire, USA.
Saifuddin NasirDepartment of Internal Medicine, University of Pittsburgh Medical Center (UPMC) Mercy Hospital, Pittsburgh, Pennsylvania, USA.
Kangning PengDepartment of Medicine, Cambridge Health Alliance, Cambridge, Massachusetts, USA.
Shayesteh JahanfarDepartment of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6149-1067

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane review (intervention). The objectives are as follows: To assess the clinical benefits and adverse effects of glucagon-like peptide-1 receptor agonist-based regimens, compared with metformin-based glucose-lowering regimens, for preventing cardiovascular events including all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, and metabolic adverse events (including transient hypoglycemia) in adults with type 2 diabetes mellitus across primary and secondary prevention settings.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsMetforminExenatideGlucagon-Like Peptide-1 ReceptorHumansIsoindolesLiraglutidePeptidesPyrazinesRandomized Controlled Trials as TopicThiazolidinedionesVenomsExenatideGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIsoindolesLiraglutideMetforminPeptidesPyrazinesThiazolidinedionesVenoms

Identifiers

PMID42573030
PMCPMC13455057

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.